Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.
Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
Age over 30 years;
BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
HbA1c between 7.5% and 10.5%.
Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
Pregnancy or lactation;
Chronic renal failure with glomerular filtration rate calculated by MDRD < 30 mL/h;
Myocardial infarction in the last than 6 months